Rockley Photonics

Rockley Photonics is pioneering a non-invasive, multi-biomarker sensing platform based on mid-infrared spectroscopy using integrated photonics. The company's core technology aims to miniaturize lab-grade analytical capabilities into wearable form factors, targeting both consumer wellness and medical diagnostics markets. After going public via a SPAC merger in 2021, Rockley has faced significant financial challenges, leading to a Chapter 11 bankruptcy filing and subsequent restructuring in 2023. The company is now focused on commercializing its sensor technology through partnerships with device manufacturers in healthcare and consumer electronics.

Integrated photonics platform using mid-infrared spectroscopy for non-invasive, multi-analyte sensing from interstitial fluid.

Rockley competes in the crowded non-invasive biosensing space against large tech giants (Apple, Samsung, Google) developing their own sensor technologies, as well as numerous startups using optical, RF, and electrochemical methods. Its success hinges on proving superior accuracy and multi-analyte capability compared to these alternatives.